Brought to you by 
Lee's gets Asian rights to Windtree's KL4 surfactant products; now gains global rights
23 Aug 2022
Executive Summary
Windtree Therapeutics Inc. licensed Lee's Pharmaceutical Holdings Ltd. exclusive rights (including sublicensing rights) to develop and commercialize its KL4 surfactant products for respiratory distress syndrome (RDS) in China, Hong Kong, Thailand, Taiwan, and 12 other Asian territories.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lee's gets Asian rights to Windtree's KL4 surfactant products; now gains global rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice